INTRODUCTION
Cardiac muscle adapts to increased pressure and/or volume with hypertrophy. This holds true for physiological stimuli, such as exercise, as well as for pathological provocations, including hypertension. Though the earliest stages appear quite similar at a morphological level, pathological cardiac hypertrophy leads to cardiovascular diseases such as heart failure and arrhythmia, whereas physiological hypertrophy does not. Thus, understanding the mechanistic distinction between these two types of cardiac growth has very important clinical implications. Numerous prior reports document transcription factors involved in pathological hypertrophy (Akazawa and Komuro, 2003; Frey and Olson, 2003) , but relatively little is known about the molecular mechanisms controlling physiological hypertrophy.
Cardiomyocytes in adult mammals retain a limited ability to proliferate in response to specific stimuli (Bergmann et al., 2009; Bersell et al., 2009; Kajstura et al., 2010) . This has potential importance because cardiomyocyte proliferation could serve as a basis for regeneration of an injured heart if it could be enhanced and harnessed. However, whether this process can be modulated through physiological interventions remains unclear. Moreover, whereas recent studies have implicated some signal transduction pathways involved in adult cardiomyocyte proliferation (Bersell et al., 2009) , little is known about the detailed molecular mechanisms and particularly the transcriptional components that are decisive in this process. Furthermore, there is little data available on factors that control cardiomyocyte proliferation in the adult heart.
One of few known regulators of cardiomyocyte proliferation is Gata4, which was recently reported to mark proliferative cells during cardiac regeneration in the zebrafish (Kikuchi et al., 2010) . This factor is also a well-known regulator of cardiomyocyte differentiation in adult hypertrophy, together with SRF, Nkx2.5, Tbx5, and Gata6 (Akazawa and Komuro, 2003) .
Here, we studied a murine model of physiological hypertrophy induced by endurance exercise, using a method termed Quanttrx, which we recently developed for genome-wide, quantitative measurement of the expression of all transcriptional components (Gupta et al., 2010) . The database underlying this method includes all known transcription factors, transcriptional coregulatory proteins, and all proteins that contain a motif that has been associated with transcriptional components, whether their function is known or not. We report here that endurance exercise effected a hypertrophic and proliferative program in cardiomyocytes, which was dependent on a reduction in the expression of the transcription factor C/EBPb, and a linked increase in the expression of CITED4. Furthermore, mice with genetically reduced C/EBPb levels recapitulated many of the cardiac phenotypes seen in exercised mice. Importantly, mice with reduced C/EBPb were resistant to the development of cardiac dysfunction in response to pressure overload on the heart.
RESULTS

Cardiac Hypertrophy and Cardiomyocyte Proliferation Are Induced following Endurance Exercise
To study transcriptional regulators of physiological cardiac hypertrophy, a ramp swimming exercise model was used (Taniike et al., 2008) . As shown in Figure S1 (available online), mild cardiac hypertrophy was induced without alterations in the expression of pathological gene markers such as ANP and BNP. There was also a 45% increase in cardiomyocyte cell size ( Figure S1 ) without any detectable difference in fibrosis or angiogenesis ( Figure S1 ). Hence, we may conclude that healthy physiological cardiac hypertrophy occurred in these animals.
Further characterization revealed that expression of the cell proliferation marker PCNA was increased in the hearts from exercised mice ( Figure 1A ). To establish the cellular origin of the increased proliferation markers, confocal microscopy was employed in cardiac tissue stained for both the cardiomyocyte-selective protein a-actinin and the proliferation marker (A) Mice swam using a ramp protocol for 2 weeks with respective controls (n = 4) and were assayed for PCNA protein levels with subsequent quantification. Data are presented as PCNA per a-tubulin after subtraction of background. Data are representative for two independent mouse cohorts. (B and C) Representative image and quantification of Ki67 (B) and phosphohistone3 (C) staining from exercised mice (green) counterstained with a-actinin (red) and DAPI (blue) in cardiac tissue. (D) Exercised and control mice were injected with BrdU 3 days prior to the final exercise day. The image shows a representative section from the exercised cohort. BrdU is labeled in green, a-actinin in red, and DAPI in blue. (E) Representative image and quantification of Aurora B kinase (green) staining from exercised mice counterstained with a-actinin (red) and DAPI (blue) in cardiac tissue. All quantifications were based on at least 80 (blinded) images from each group (from at least four mice). Any uncertainty concerning whether a ki67-, AuroraB-, or BrdU-positive cell was completely within an a-actinin-positive area was resolved using confocal Z stacks. Error bars represent standard error of mean. *p < 0.05 versus respective control using Student's t test. See also Figure S1 . ki67. Robust ki67 staining was seen in 1%-5% of cardiomyocytes ( Figure 1B) . Importantly, there was a significant increase in cardiomyocyte ki67 staining in the exercised mice compared to the nonexercised controls, as judged from blinded analyses of histological sections using digital software. The more specific mitosis marker, phospho-Histone3 (pH3), was also elevated ( Figure 1C ), though the absolute number of positive cells was relatively low. Figure S1 shows pH3-positive cardiomyocytes in the different stages of mitosis. Thus, markers of both cell size and proliferation are elevated in the cardiomyocytes of mice in this model of physiological hypertrophy.
Previous studies have utilized the density of cardiomyocyte nuclei as an indicator of cardiomyocyte proliferation (Bersell et al., 2009) . We could detect a small increase in nuclear density (100% and 132% in controls versus exercised mice, respectively; p = 0.07), but this did not reach statistical significance. However, it is worth noting that the observed increase in cardiomyocyte size would be expected to confound/dilute the calculated changes in nuclear density. DNA biosynthesis was therefore assayed using bromodeoxyuridine (BrdU) injections in mice undergoing this exercise protocol. We could detect double-a-actinin and BrdU-positive cardiomyocytes at a frequency of 1%-6% in exercised mice. Figure 1D shows a substantial increase in BrdU-positive cardiomyocytes in the hearts of exercised mice compared to the controls. Importantly, Z stack visualization of positive cells clearly demonstrates a distinct cardiomyocyte localization of the BrdU ( Figure S1 ).
Finally, staining for the cytokinesis marker Aurora B kinase was used to demonstrate that the exercise protocol did indeed promote completed cardiomyocyte cell division ( Figure 1E ). Conversely, we could not detect any of these changes in proliferation markers in a murine model of pathological hypertrophy (data not shown). Taken together, these data strongly suggest that adult cardiomyocytes increase in both size and proliferation rate in response to this form of endurance exercise.
C/EBPb Is Downregulated during Physiological Hypertrophy
To investigate the transcriptional basis of physiological cardiac hypertrophy, we utilized Quanttrx, a qPCR-based screen that we recently developed against all known and predicted transcriptional components (Gupta et al., 2010) . We used cardiac samples from the mice characterized (above) together with cardiac samples from mice subjected to transaortic constriction (TAC) for 2 weeks. As shown in Figure S1 , the TAC procedure induced a similar degree of hypertrophy as seen in the exercised animals but with elevation of ANP/BNP, thus indicating pathological hypertrophy. There were no signs of heart failure or other pathological changes in the mice subjected to TAC at this time point.
The Quanttrx screen identified 175 genes significantly regulated in the exercise model and 96 in the pathological (TAC) model (Table S1 and Table S2 ). Importantly, there was little overlap in the expression profile between the two models. In fact, there was a significant, negative correlation between the changes induced in the respective model ( Figure S2 ; r = À0.32; p < 0.001). Thus, these models of pathological and physiological hypertrophy express distinct programs of transcriptional components.
Of the 175 transcription factors regulated by physiological hypertrophy, 47 (27%) had no known function (no PubMed annotation). However, 10 transcription factors with known functions in cardiac differentiation and/or adult hypertrophy were differentially regulated in the swim model. These included wellknown genes such as Nkx2.5, Gata4, Tbx5, Mef2c, and Gata6. Furthermore, 13% of the differentially expressed factors had known or suggested roles in cellular proliferation. Less than 1% of the genes regulated in the pathological model had any known role in cellular proliferation.
Based on the magnitude of expression changes and absolute cardiac expression, we chose 30 genes out of this preliminary list of 272 and performed qPCR analyses in completely new samples of either physiological (endurance exercise) or pathological (TAC) hypertrophy. Eight out of these 30 showed robust validation ( Figure S2 and Figure 2A ), and these were further analyzed for cardiomyocyte-specific expression. Figure S2 shows expression of these genes in cardiomyocytes and noncardiomyocytes after density gradient separation. Five out of eight were expressed primarily in the cardiomyocyte fraction, and these were subsequently analyzed using adenoviral-mediated forced expression and/or siRNA-mediated knockdown, using changes in cell size of rat neonatal cardiomyocytes as our endpoint. Gbx2, Cited4, Mlx, and Meox1 failed to demonstrate any effect on cardiomyocyte sizes ( Figure S2 ), but reduction of C/EBPb caused a clear increase in cell size ( Figure 3A) . C/EBPb is a member of the bHLH gene family of DNA-binding transcription factors and has known roles in cell proliferation and differentiation in other tissues (Sebastian and Johnson, 2006) , including adipose cells and liver. However, it has not been studied in the context of the cardiomyocyte. C/EBPb mRNA expression was reduced by 61% in hearts in the exercise model when assayed in new samples, but this effect was not observed in a model of pathological hypertrophy using transverse banding (TAC) performed in parallel (Figure 2A) . Downregulation of C/EBPb was also seen in response to the exercise training at the protein level ( Figure 2B) . Expression of the short LIP C/EBPb isoform that is inhibitory toward C/EBPb function was undetectable in these cardiac samples ( Figure 2B ). Confocal microscopy illustrated that it was indeed cardiomyocyte-specific expression of C/EBPb that was reduced with exercise (Figure 2C) . Consistent with this, C/EBPb expression was enriched in the cardiomyocyte fraction, versus noncardiomyocyte cells, following gradient purification of rat neonatal cardiomyocytes ( Figure 2D and Figure S2 ).
Two additional mouse models of exercise were tested for effects on C/EBPb expression: acute and low-intensity treadmill running. Neither treatment resulted in cardiac hypertrophy (data not shown), but reduction of C/EBPb expression occurred in the acute setting (40 min of treadmill running), as seen in Figure 2E . Thus, C/EBPb expression is reduced relatively early in endurance exercise.
Reduction in C/EBPb Expression Induces Hypertrophy and Proliferation in Cultured Cardiomyocytes
The functional consequences of experimental reduction of C/EBPb were assessed in detail in primary rat cardiomyocytes. An siRNA was used to reduce C/EBPb levels to approximately the levels of mRNA observed after endurance exercise (43%) ( Figure S3 ). As demonstrated in Figures 3A and 3B , the forced decrease in C/EBPb mRNA was sufficient to drive an increase in cell size and in the rate of protein biosynthesis. No statistically significant change in cell size or protein biosynthesis was seen with forced C/EBPb expression (p = 0.42 and p = 0.054, respectively). The reduction of C/EBPb expression was also sufficient to ablate the increase in ANP levels seen with pathological provocation ( Figure S3 ).
Interestingly, the C/EBPb reduction via siRNA also led to an increase in cell number ( Figure 3C ). This was accompanied by increased PCNA expression and increased BrdU incorporation into DNA, highly suggestive of cardiomyocyte proliferation ( Figures 3D and 3E ). These data indicate that a reduction in C/EBPb expression is sufficient to induce hypertrophy and proliferation in cultured cardiomyocytes.
C/EBPb Regulates Expression of a Gene Set Characteristic of Physiological Hypertrophy by Sequestering Serum Response Factor
The initial Quanttrx screen revealed a specific set of regulated genes with known functions in cardiomyocyte differentiation and hypertrophy ( Figure 4A and Table S1 ). Examples of such genes were Gata4, Tbx5, and Nkx2.5, which all induce hypertrophy (Akazawa and Komuro, 2003) . Beyond these 11 genes, we also investigated expression levels of the genes that are well known to be altered in cardiac hypertrophy or differentiation, including a-MHC, TnI, and TnT, which were all upregulated in the hearts of exercised mice ( Figure 4A ). The transcriptional coregulator PGC-1a has previously been demonstrated to have an important role in preventing cardiac dysfunction after the development of hypertrophy (Arany et al., 2006) , and exercised mice indeed displayed increased cardiac expression levels of PGC1a together with its downstream targets VEGF, Ndufs1, Ndufv2, and ATP5o ( Figure 4A ). Thus, by combining the Quanttrx screen hits with markers of hypertrophy and the PGC-1a, as well as its downstream targets, we defined an exercise-induced gene set of 19 genes ( Figure 4A ). The changes in mRNA expression for Nkx2.5, Tbx5, Mef2c, Gata4, and PGC-1a following TAC surgery are shown in Figure S4 .
As shown in Figure 4B , reduction in C/EBPb levels in primary cardiomyocytes resulted in a strikingly similar expression pattern. In fact, 11/19 of these genes were regulated in the same manner as in the exercise model (p < 0.001 using chi-square statistics). Furthermore, adenoviral expression of C/EBPb induced essentially the reverse expression pattern ( Figure S4 ). These data strongly suggest that C/EBPb acts upstream of other transcrip- (E) Cardiac C/EBPb mRNA levels from three different exercise regimens: acute = 40 min treadmill running (n = 6); ''low intensity'' = 2 weeks of 30 min daily running (n = 6); ''endurance'' = the swimming protocol as described in methods (n = 4). Error bars represent standard error of mean. *p < 0.05 versus respective control using Student's t test. See also Figure S2 . tional components that are also regulated in physiological hypertrophy. Especially interesting was the C/EBPb-dependent regulation of Gata4, which has recently been demonstrated to play a major role in zebrafish cardiomyocyte proliferation during myocardial regeneration (Kikuchi et al., 2010) .
Many of the genes regulated by both endurance exercise and the siRNA-mediated C/EBPb reduction are known to be transcriptional targets of the transcription factor SRF, with SRE elements in their promoters (Akazawa and Komuro, 2003) . C/EBPb has been demonstrated to physically interact with SRF (Hanlon and Sealy, 1999) , but the functional consequences of this interaction are not clear, especially in cardiomyocytes in which the role of C/EBPb is unknown. Previous reports on the C/EBPb-SRF interaction have suggested a positive effect on SRE-dependent elements, but the increased expression levels of Gata4 and a-MHC ( Figure 4A ) following C/EBPb siRNA here suggested a negative regulation of SRE-dependent genes in cardiomyocytes.
A physical interaction between the SRF and C/EBPb proteins was indeed observed using coimmunoprecipitation from primary cardiomyocytes ( Figure 4C ). Next, chromatin immunoprecipitation (ChIP) assays were performed, examining the binding of SRF to the Gata4 and a-MHC promoters following gain and loss of the C/EBPb protein. As shown in Figure 4D , CEBPb reduction using siRNA dramatically increased SRF binding to the promoters of both a-MHC and Gata4, in which SRF is known to play a positive regulatory role. Conversely, adenoviral expression of C/EBPb reduced SRF binding to these promoters. Thus, C/EBPb interferes with SRF binding to the promoters of critical cardiac genes ( Figure 4E ).
The recent discovery of the ErbB4 pathway in cardiomyocyte proliferation led us to investigate whether C/EBPb could be affected by such signaling. This was especially interesting as ErbB4 signals via AKT1, a kinase known to function in physiological hypertrophy (DeBosch et al., 2006) . We thus investigated the connection of this pathway to C/EBPb using both forced expression of wild-type AKT1 and a dominant-negative AKT1 (Nagoshi et al., 2005) . As demonstrated in Figure S4 , increasing AKT1 activity did indeed reduce C/EBPb expression levels together with an expression profile resembling what was observed with exercise with increased expression of Tbx5, Gata4, TnI, and a-MHC. Conversely, the dominant-negative AKT1 mutant increased C/EBPb in parallel with decreased mRNA levels of Tbx5, Gata4, TnI, TnT, and a-MHC. We could thus conclude that AKT1 activity evokes the same gene expression profile as seen in exercise. We next used C/EBPb adenovirus together with AKT1 overexpression to establish whether C/EBPb indeed 
C/EBPb Negatively Regulates CITED4, a Transcription Factor Promoting Cardiomyocyte Proliferation
The SRF-dependent gene set described above includes well-known regulators of cardiomyocyte hypertrophy, but apart from Gata4, they are not known to participate in a proliferative phenotype, such as we see with C/EBPb reduction. We thus analyzed the list of exercise-induced cardiac genes ( Figure S2 ) for those controlled by C/EBPb that might influence or control cardiomyocyte proliferation. Preliminary studies using gain and loss of function for six factors apparently downstream of CEBPb led us to focus on CBP/p300-interacting transactivator with ED-rich carboxyterminal domain 4 (CITED4). Indeed, CITED4 showed a robust increase in exercised hearts ( Figure 5A) , and its expression level was markedly altered with C/EBPb gain or loss of function in vitro ( Figure 5B) . Strikingly, forced CITED4 expression ( Figure S5 ) increased cardiomyocyte cell numbers together with an increased percentage of ki67-positive cells ( Figures 5C and 5D) . Conversely, siRNA directed against CITED4 ( Figure S5C ) reduced both cell numbers and ki67 staining ( Figures 5C and  5D ). Gene expression analysis also revealed a gene set of proproliferative genes increased in endurance exercise (Figure S5) , in which the important cell cycle/proliferation factors CyclinD1 and n-myc also displayed increased expression with forced CITED4 expression together with SRF ( Figure S5) .
To investigate the functional relationship between C/EBPb and CITED4, we used siRNA directed against CITED4 together with C/EBPb siRNA. As shown in Figure 5E , CITED4 knockdown could completely abolish the effect of cellular proliferation seen with the C/EBPb reduction. Thus, C/EBPb is likely to mediate its antiproliferative effects, at least in part, via CITED4 expression.
C/EBPb Controls Cardiomyocyte Proliferation in the Zebrafish Embryo
We next tested the role of C/EBPb reduction in zebrafish, a simple and experimentally accessible in vivo system. Anti-C/EBPb morpholino oligonucleotides were injected into zebrafish embryos transgenic for cmlc2-GFP at the one-cell stage ( Figure 6A ). Figure 6B shows zebrafish hearts dissected at 36 hr and stained for nuclei (DAPI, blue) and plasma membrane (integrin, red). Quantification of these images revealed increased cardiomyocyte cell number but did not change cardiomyocyte size up to 72 hr postfertilization ( Figure 6D ). Furthermore, 20 min BrdU labeling of 48 hr hpf embryos demonstrated increased DNA synthesis ( Figure 6C and quantification in Figure 6E ). Of note, Gata4 mRNA expression was significantly increased, consistent with results shown above ( Figure 6F ). Thus, reduction of C/EBPb induces cardiomyocyte proliferation in zebrafish hearts in vivo.
Heterozygosity for C/EBPb in Mice Mimics Cellular Aspects of Endurance Exercise and Is Cardioprotective against Pressure Overload
Mice with a complete loss of C/EBPb show preand perinatal lethality, but heterozygotes are relatively normal. Mice heterozygous for C/EBPb have cardiac C/EBPb mRNA levels reduced to a similar level as observed in exercised mice (50% reduction) ( Figure S6 ). These heterozygous animals were therefore used to study the role of this factor in mammalian cardiac function. The exercise-induced gene set defined above was analyzed in hearts of the C/EBPb +/À compared to wild-type littermates, and a pattern of expression changes similar to that seen with exercise was seen for multiple genes (8 of 19 genes) ( Figure S6 ). Furthermore, measurements of cell size (done in a blinded manner) revealed cardiomyocyte hypertrophy ( Figure 7A ) and an increase in heart weight (Figure S6) . Echocardiographic studies revealed a small but significant increase in fractional shortening, an important parameter of improved heart function (Table S3 ). No differences in heart wall thickness were observed. Cardiomyocyte proliferation was also assayed at baseline in the C/EBPb +/À mice. Notably, there was a clear increase in cardiomyocyte nuclear density ( Figure 7B ), consistent with increased expression of proliferation markers in the cardiomyocytes that was also observed ( Figure S6 ). BrdU injections resulted in an increased number of positive cardiomyocytes in the C/EBPb +/À mice ( Figure 7C and Figure S6 ). We also detected Aurora B kinase-positive cardiomyocytes in C/EBPb +/À cardiac tissue ( Figure 7D ). To study adult cardiomyocyte proliferation directly, we also isolated adult cardiomyocytes from C/EBPb +/À mice and littermate controls, incubated them in culture with BrdU for 48 hr, and stained for proliferation markers. Fewer than 0.05% ± À0.1% of cardiomyocytes from control mice were BrdU positive. However, cells from the C/EBPb +/À mice displayed a 10-fold increase in positive nuclear staining (0.6% ± 0.2% of cells; p < 0.05 compared to control) ( Figure 7E ). We next performed the exercise protocol on the C/EBPb +/À mice together with littermate controls. As shown in Figure S7 , there was no further reduction in C/EBPb levels with exercise in the C/EBPb +/À mice compared to wild-types. In addition, we could only detect a minor increase in heart mass in the exercised C/EBPb +/À mice ( Figure S7 ). More interestingly, however, the C/EBPb +/À mice displayed a clear increase in exercise capacity at baseline ( Figure S7 ), suggestive of a functional consequence of C/EBPb reduction in vivo.
To critically assess the possible protective role of the cardiac changes seen in the C/EBPb +/À mice, we performed transverse aortic constriction (TAC) to induce pressure overload on the heart leading to pathological cardiac hypertrophy and dysfunction in mice. As expected, TAC resulted in progressive reduction in cardiac function, as judged by fractional shortening (FS) in the wild-type mice. However, the C/EBPb heterozygous mice displayed only a minor reduction in contractile function after TAC ( Figure 7F ). Pulmonary edema is a very important characteristic of cardiac failure in both mice and humans, and the differences in heart function between the two groups were also supported by a significant difference in lung weight ( Figure 7G ). Ventricular dilatation (as a marker of cardiac failure) also increased more rapidly in the wild-type mice than in the C/EBPb +/À animals ( Figure S7 ). According to our IACUC rules, mice subjected to TAC had to be sacrificed when cardiac function (fractional shortening) decreased by at least four standard deviations from the mean, as this represents a very substantial deterioration likely to be associated with heart failure. Using such criteria, Kaplan-Meier analysis demonstrated that wild-type littermates were significantly more likely to develop this degree of cardiac dysfunction after TAC than C/EBPb +/À littermates ( Figure 7H ). Thus, the reduction in C/EBPb expression in the hearts of heterozygous mice, quantitatively comparable to that seen after exercise training, results in improved cardiac function and resistance to a heart-specific pathological stress.
DISCUSSION
Despite the well-documented beneficial cardiovascular effects of exercise, our understanding of the mechanisms underlying these benefits, particularly in the heart, remains very limited. In particular, little is known about the transcriptional pathways underlying physiological hypertrophy, as compared to the wide variety of transcription factors implicated in pathological hypertrophy. Here, we provide evidence for a cardiac pathway induced by exercise and mediated by the reduction of C/EBPb, resulting in physiological hypertrophy. Interestingly, exercise or experimental decreases in C/EBPb expression induce increases in both cardiomyocyte size and cell division, which are likely to contribute to some of the benefits observed. Moreover, these effects were tightly coupled to a beneficial (E) Rat neonatal cardiomyocytes treated with control siRNA, C/EBPb siRNA + control siRNA, or C/EBPb siRNA + Cited4 siRNA, followed by assay of BrdU incorporation as previously described. Data is pooled from three experiments and presented as percent of control. Error bars represent standard error of mean. *p < 0.05 versus respective control, and x versus C/EBPb siRNA using one-way ANOVA statistics. T test was used for (A-D). See also Figure S5 . metabolic gene set, including an induction of the PGC1a pathway. Lastly, we observe that reduction in C/EBPb expression was itself sufficient to result in improved cardiac function and resistance to pathological changes/lethality induced in the heart by pressure overload. Considerable attention has recently been focused on the potential for cardiomyocytes to proliferate, illustrated in several recent papers (Bergmann et al., 2009; Bersell et al., 2009; Kajstura et al., 2010) . In fact, the proliferative behavior observed here in cardiomyocytes caused by the endurance exercise was quantitatively similar to that seen with NRG1 treatment previously (Bersell et al., 2009) . Data presented here also suggest that C/EBPb is an important functional target of ErbB4-related signaling pathways, particularly AKT1, in cardiomyocytes.
Exercise and genetic reduction of C/EBPb both resulted in the induction of a specific gene set in vitro and in vivo that is known to influence cardiac function. Tbx5, Nkx2.5, Gata4, and a-MHC have all been demonstrated to induce hypertrophy in adult cardiomyocytes (Akazawa and Komuro, 2003) . It is thus likely that C/EBPb exerts part of its hypertrophic actions via increases in this important gene set. It is also worth noting that these effects of reduced C/EBPb expression do not require massive changes in mRNA or protein levels; 50%-60% changes through exercise or genetic alterations are sufficient to bring about rather profound changes in cardiomyocyte biology and the in vivo response to biomechanical stress. This strongly suggests a rheostat-like role for C/EBPb, whereby small but highly regulated changes in this factor are reflected in a broad downstream response in the heart. Among affected genes was also PGC1a, a transcriptional coactivator that is important for mitochondrial biogenesis and protection against pathological heart stress ( Arany et al., 2006; Finck and Kelly, 2007) . As gain-of-function studies in vitro did not suggest that PGC1a induces cardiomyocyte hypertrophy, it is more likely that PGC1a acts via increased mitochondrial gene expression and function.
A key mechanism by which C/EBPb controls Gata4 expression is through binding to SRF and sequestering this factor from direct binding to the Gata4 (and a-MHC) promoters. This mechanism of action may have rather broad implications for cardiac biology considering the available data on the crucial role of SRF in cardiomyocyte differentiation and the regulation of expression of Tbx5, Gata, and Nkx2.5 (Akazawa and Komuro, 2003; Chai and Tarnawski, 2002) . In fact, ablation of SRF is the only known genetic knockout model that completely abolishes cardiomyocyte differentiation (Fukushige et al., 2006) . Possible cardioprotective effects of C/EBPb reduction are also consistent with recent reports that have described increased C/EBPb DNA binding in pathological models for negative cardiac remodeling (Oh et al., 2010) .
CITED4 was originally cloned 8 years ago Yahata et al., 2002) , but very little is known about its function. We demonstrate here that CITED4 is expressed in the heart, and its expression is increased with exercise. CITED4 levels are negatively regulated by C/EBPb expression, whereas experimental alterations of CITED4 levels in primary cardiomyocytes (E) Immunohistochemistry against phosphohistone H3 (green) in primary cardiomyocyte from an adult C/EBPb +/À mouse heart counterstained with a-actinin (red) and dapi (blue).
(F) Wild-type and C/EBPb +/À (n = 6 and 7) mice subjected to TAC and assayed for fractional shortening at indicated times.
(G) Lung weight 52 days after TAC intervention.
(H) Kaplan-Meier plot of cardiac failure-free fraction at indicated times in wild-type and C/EBPb +/À mice following TAC procedure.
Error bars represent standard error of mean. *p < 0.05 versus respective control using Student's t test. **p < 0.01. See also Figure S7 .
regulate proliferation. Forced expression of CITED4 also increased levels of cyclin D1, which is known to drive cardiomyocyte proliferation (Campa et al., 2008) . Thus, it is highly plausible that C/EBPb exerts its antiproliferative actions via inhibition of CITED4 expression. However, we cannot exclude the possibility that other pathways might also contribute. C/EBPb reduction in the zebrafish embryo induced significant proliferation that, together with data provided from mice, suggests an evolutionarily conserved pathway in cardiomyocytes. There was no effect on cardiomyocyte size in the fish embryos; this could reflect a species difference or could be explained by the particular developmental stage at which the oligonucleotides were utilized.
The C/EBPb heterozygous mouse closely phenocopied the endurance exercise model, as judged from cardiac hypertrophy, cardiomyocyte proliferation, and expression of key genes of cardiac function. In fact, 42% of the gene set analyzed was regulated in the same manner by both of these perturbations in vivo. The magnitude of the effect on hypertrophy at baseline, however, was smaller than in the exercised mice, suggesting that additional pathways are likely to contribute to the changes induced in physiological hypertrophy.
Although exercise has well-known positive health effects, possible benefits of physiological cardiac hypertrophy remain unclear (such as improved outcome following pathological provocations) in either mice or man. However, we were able to demonstrate that hearts in C/EBPb heterozygous mice had improved tolerance to pressure overload. This included resistance to deterioration in cardiac function (fractional shortening) after transverse constriction and improved survival. These data are also important because transverse constriction is a very selective stress to the heart and thus would not be confounded by systemic effects of reduced C/EBPb in the total body heterozygotes. Mechanistically, the increase in cardiomyocyte proliferation could possibly contribute to the functional resistance to cardiac dysfunction; such an effect would be in accordance with resistance to injury connected to proliferation observed in other systems (Bersell et al., 2009 ). However, improved cellular energetics (via increased PGC1a expression), physiological cellular hypertrophy, or other functional alterations could also be important contributing factors. Better understanding of the pathways affecting C/EBPb protein expression, or drugs that suppress C/EBPb expression in the heart, could be of significant clinical value in cardiac pathological states.
EXPERIMENTAL PROCEDURES Material
A list of utilized primers is presented in Table S2 . Antibodies against PCNA, tubulin, C/EBPb, actin, CITED4, ki67, phospho-Histone 3, Aurora B, BrDU, b-tubulin, a-actinin, and nonimmune IgG were from Abcam. Antibodies to SRF and C/EBPb were from Santa Cruz Biotechnology. HRP-conjugated secondary antibodies were from Jackson ImmunoResearch Laboratories. Alexa Flour (488 and 633) conjugated antibodies were from Invitrogen. Precoated plates were from BD bioscience. Chamber slides for microscopy were from Nalge Nunc International. BioPix iQ 2.0 were obtained from BioPix AB (Gothenburg, Sweden). 35S-Methionine was purchased from Perkin Elmer (Boston, MA). The chromatin immunoprecipitation kit was from Cell Signaling.
Mice Cohorts
For the swimming experiments, 12-week-old B6 mice were used (purchased from the Jackson Laboratory, Bar Harbor, ME). C/EBPb heterozygous mice were purchased from the Jackson Laboratory, and all wild-type controls used were age-matched littermates. The following IACUC-approved protocols controlled the experiments: 005-2009, 110-2008, 056-2008 , and #04650.
Swimming Exercise Protocol
Endurance exercise was carried out as described (Taniike et al., 2008) . In brief, mice swam in a ramp protocol starting at 10 min two times daily, with 10 min increase each day until 90 min, two times per day was reached. The protocol was ended after 14 days. The mice were closely observed at all times to avoid relative hypoxia. With this protocol and using these mice strains, there were no events of mice submerging under the water surface.
Transverse Aortic Constriction
Transverse aortic constriction (TAC) was carried out as described in Arany et al. (2006) using a 27 gauge needle. Subsequently, mice were followed weekly using echocardiography and sacrificed at fractional shortening < 30 (4 SD below baseline) and/or cachexia.
Echocardiographic Studies
Cardiac sonograms were carried out as described (Arany et al., 2006) . In brief, the heart was first visualized in long/short axis views followed by m-mode analysis of short axis. Care was used to obtain exactly symmetrical short axis images at the level of papillary muscles. At least three measurements were obtained and averaged for every data point from each mouse.
RT-PCR
QPCR was carried out following standard procedures using SYBR green. All data were normalized to 18S or indicated housekeeping gene, and quantitative measures were obtained using the delta-delta-CT method. A list of primers can be found in Figure S2 .
Western Blot and Quantification and Coprecipitations
Protein amounts from all samples were assessed using the BCA-kit (Thermo Scientific) followed by protein concentration normalization prior to all western blot experiments. Western blot was carried out following standard procedure, and final band intensity (QL-BG) was quantified using BioPix iQ (Boströ m et al., 2010) . All data was normalized to background and loading controls. Precipitation of SRF was carried out as described in (Boströ m et al., 2007) .
Adenoviral Construction and Preparation
Clones for CITED4 and C/EBPb were purchased (Imagenes) as shuttle vectors and moved to the pAD/CMV/V5-DEST vector using Gateway recombination (Invitrogen) in accordance with manufacturer's instructions. Adenoviruses were then produced using the ViraPower Adenoviral Expression System (Invitrogen), and viral stocks were purified using Vivapure Adenopack 100 (Sartorius Stedim Biotech). An MOI of 20 was used for all overexpression experiments in primary cardiomyocytes. Characterization of overexpression is shown in Figure S4 and Figure S6 . Adenovirus expressing AKT and the dnAKT was used as described in Matsui et al. (2003) and Nagoshi et al. (2005) .
Immunohistochemistry from Frozen Sections
Tissues were snap frozen in OCT in liquid nitrogen and sectioned at 10 mm. For staining, sections were fixed in 50% and 100% Acetone followed by washing in PBS. Next, samples were incubated in 5% BSA, 0,1% Triton x-100, PBS (buffert A) for 1 hr. After additional washing, slides were incubated overnight with primary antibody in buffer A and thereafter in secondary antibody for 1 hr. Finally, slides were washed extensively in PBS for 30 min and mounted in Prolong Gold with DAPI (Invitrogen).
Confocal Microscopy and Image Quantification
Samples were visualized using a Leica SP5 confocal microscope at 403 magnification using standard procedure. All imaging was performed with group identity blinded whereby at least 20 random images were obtained from each slide or group. Images were then quantified in BioPix iQ 2.0 in accordance with manufacturer's instructions (Boströ m et al., 2007; Hulté n et al., 2010) .
BrdU Injections and Subsequent Staining Procedure
BrdU was injected intraperitoneally 3 days prior to the end of the swim protocol at 50 mg/kg. Cardiac sections were obtained as described above, and prior to staining, the slides were incubated in 1 M HCl for 10 min on ice, followed by 2 M Hcl for 10 min room temperature and 20 min in 37 degrees. Slides were then washed with 0.1 M Borate buffer 10 min and rinsed in PBS. Thereafter, the previously described protocol for immunohistochemistry was utilized.
Rat Neonatal Primary Cardiomyocyte Culture and Transfections
Primary rat neonatal cardiomyocytes were prepared as described in Aoyama et al. (2005) with gradient centrifugation purification of cardiomyocytes. siRNA transfections were carried out using Lipofectamine 2000 (Invitrogen) as recommended by manufacturer and as described in Boströ m et al. (2007) . Two validated siRNA constructs against C/EBPb and CITED4 with respective controls were purchased from Sigma Aldrich. Following examination of knockdown and lack of off-target effects, the most effective construct was used for subsequent studies.
Primary Adult Cardiomyocyte Preparation
Primary mouse cardiomyocytes were isolated following Langendorf perfusion as described (Liao and Jain, 2007) .
Nuclear Density Quantification
Nuclear density was assessed as described for ''image quantification'' above using confocal images. The number of a-actinin-positive DAPI nuclei per area of a-actinin-positive cells was used.
Treadmill Exercise
The acute exercise protocol included 40 min of forced exercise on a 0% incline treadmill (Columbus Instruments). The mice were trained twice briefly prior to experiment. The long-term running was carried out 5 days per week for 4 weeks at a warmup speed of 5 m/min for 5 min. Every subsequent 5 min, the speed was increased by 5 m/min until a maximal speed of 20 m/min was reached to a maximum of 1 hr running. Estimate of maximal exercise capacity was performed using a V02-max treadmill with a ramp protocol maximizing running within 15 min at 20 degrees incline. Watts were calculated from the incline per minute and mouse weight.
Cell Size Measurements and Quantification In Vitro and In Vivo
Cell size measurements from cardiac tissue were performed from WGAstained tissues (Invitrogen) in which only exactly cross-sectional cells (hexagonal) were used for BioPix iQ area measurements.
Protein Biosynthesis Assay
Protein biosynthesis was assessed in vitro after incubation with methioninefree medium followed by a 1 hr pulse of 500 mCi/well 35S-Met. Cells were then scraped, and protein was extracted using TCA (Boströ m et al., 2007) .
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed using the Simple ChIP kit (Cell Signaling) in exact accordance with manufacturer's instruction. In brief, ten 10 cm dishes were used in triplicates for all groups, and chromatin complexes were fixed using formaldehyde. Next, nuclear fractions were isolated, and DNA was digested enzymatically. The quality and length of digested fragments were verified on 1.5% gels. Finally, SRF was immunoprecipitated in parallel with nonimmune IgG control, and DNA was extracted from complexes. DNA was analyzed for presence of Gata4 or myh6 promoter fragments containing SRE sites (primers used are presented in Table S2 ).
Zebrafish Experiments
An antisense morpholino directed against C/EBPb or a control morpholino was injected as described (Milan et al., 2006) at the one-cell stage. Embryos were then analyzed at 24 or 36 hr as described. Morpholinos (Genetools) used were CCTCGTAAAAACCGGCCACTTCCAT for C/EBPb and CCTCTTACCTCAGT TACAATTTATA for control.
Statistical Analysis
Data are presented as mean ± SEM unless otherwise indicated. Unpaired, two-sided Student's t test was used when indicated, with p < 0.05 considered statistically significant. When assessing multiple groups, one-way ANOVA was utilized with turkeys post hoc test. Kaplan-Meier statistics were performed using Gehan-Breslow-Wilcoxon test. The statistical software used was SPSS 17.1.
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